BIO-TECHNE TO PRESENT AT THE UBS MEDTECH, TOOLS AND GENOMICS SUMMIT 2023

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced that its CFO will present at the UBS MedTech, Tools and Genomics Summit 2023 on August 17, 2023. Bio-Techne is a leading developer and manufacturer of high-quality purified proteins and reagent solutions. In fiscal 2023, the company generated approximately $1.1 billion in net sales.

MINNEAPOLIS, Aug. 15, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the UBS MedTech, Tools and Genomics Summit 2023 on Thursday, August 17, 2023, at 10:00 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023 and has approximately 3,200 employees worldwide.

Contact:

David Clair, Vice President, Investor Relations & Corporate Development David.Clair@bio-techne.com 612-656-4416

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-ubs-medtech-tools-and-genomics-summit-2023-301900534.html

SOURCE Bio-Techne Corporation

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is Bio-Techne Corporation.

When will the CFO of Bio-Techne present at the UBS MedTech, Tools and Genomics Summit 2023?

The CFO of Bio-Techne will present on August 17, 2023, at the summit.

What does Bio-Techne specialize in?

Bio-Techne specializes in the development and manufacturing of high-quality purified proteins and reagent solutions.

How much net sales did Bio-Techne generate in fiscal 2023?

Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023.